Kidney Week 2019 — Atrasentan reduces the risk of renal events in T2D and chronic kidney disease

Treatment with a low-dose endothelin A receptor antagonist in type 2 diabetes reduces albuminuria without causing sodium retention, but long treatment effects on renal outcomes are unknown.